Wall Street analysts expect that Zosano Pharma Corp (NASDAQ:ZSAN) will post earnings per share of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Zosano Pharma’s earnings. Zosano Pharma posted earnings per share of ($0.46) in the same quarter last year, which indicates a positive year over year growth rate of 47.8%. The company is scheduled to report its next quarterly earnings report on Wednesday, March 7th.
On average, analysts expect that Zosano Pharma will report full-year earnings of ($0.90) per share for the current fiscal year. For the next financial year, analysts expect that the firm will report earnings of ($0.90) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Zosano Pharma.
Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05).
Shares of Zosano Pharma (ZSAN) opened at $0.50 on Thursday. Zosano Pharma has a 1-year low of $0.50 and a 1-year high of $3.54. The stock has a market capitalization of $20.72, a price-to-earnings ratio of -0.43 and a beta of 2.50.
In other Zosano Pharma news, Director Kenneth Greathouse bought 95,000 shares of the stock in a transaction on Friday, December 1st. The shares were purchased at an average cost of $0.62 per share, with a total value of $58,900.00. Following the completion of the transaction, the director now directly owns 95,000 shares of the company’s stock, valued at approximately $58,900. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 200,000 shares of company stock worth $123,450 over the last three months. Company insiders own 2.83% of the company’s stock.
A hedge fund recently raised its stake in Zosano Pharma stock. Northern Trust Corp boosted its holdings in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,234 shares of the biotechnology company’s stock after buying an additional 67,774 shares during the quarter. Northern Trust Corp owned about 0.20% of Zosano Pharma worth $112,000 at the end of the most recent quarter. 19.41% of the stock is owned by institutional investors.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.